Since it went on the market, the newer device has been the subject of several reports of hemolysis. This would seem ...

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Boston Scientific has obtained CE mark for its newest transcatheter aortic valve replacement technology. The Marlborough, MA-based company’s Acurate Prime system is indicated to restore function and ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...